Double-blind, randomized sham controlled study of deep-TMS add-on treatment for negative symptoms and cognitive deficits in schizophrenia
Rabany, L., Deutsch, L., & Levkovitz, Y. (2014). Journal of Psychopharmacology, 4;28(7):686-690.
The study examined Brainsway® Deep TMS (Transcranial Magnetic Stimulation) as an add-on treatment for negative symptoms and cognitive deficits in schizophrenia. In the study, 30 patients were randomly assigned to receive real or sham Deep TMS (20 sessions), where both patients and operators were not aware of the type of treatment. In the study, negative symptoms significantly decreased in the group that received real Deep TMS treatment.
Brainsway's international website includes clinical and regulatory data for indications which were not cleared by the FDA for use in the United States.
This site is not intended for residents of the United States, its territories, and Puerto Rico.
The FDA cleared Brainsway's Deep TMS system for use in the U.S for treatment of depressive episodes in adult patients suffering from Major Depressive Disorder who failed to achieve satisfactory improvement from previous anti-depressant medication treatment in the current episode.
Would you like to proceed to the international website? To proceed click here
or click here to close this window